Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|21|3311-3319

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.21, 2014-11, pp. : 3311-3319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of gemcitabine, cisplatin, and S‐1 combination therapy for patients with untreated advanced biliary tract cancer

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 9, 2015-09 ,pp. : 669-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma

By  

CANCER CYTOPATHOLOGY, Vol. 126, Iss. 1, 2018-01 ,pp. : 54-63

John Wiley & Sons Inc

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

A Phase II Multi-Center Study of Triple Therapy with Paclitaxel, S-1 and Cisplatin in Patients with Advanced Gastric Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 76-83

Karger

Access to resources Recommend Favorite

Pemetrexed in the treatment of malignant pleural mesothelioma

By Peake Michael D  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 569-575

Future Medicine

Access to resources Recommend Favorite